NCT02580708 - Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 5, 2016

Study Completion Date

June 27, 2016

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Rociletinib

DRUG

Trametinib

Trial Locations (4)

Virginia Cancer Specialists, Fairfax

Levine Cancer Institute, Charlotte

Tennessee Oncology, PLLC - The Sarah Cannon Research Institute, Nashville

Washington University School of Medicine, St Louis